ClinicalTrials.gg
TerminatedNCT00433017Updated Apr 21, 2011Results posted

Verteporfin Photodynamic Therapy Administered in Conjunction With Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration (AMD)

A Phase 2/3 interventional study of Verteporfin Photodynamic Therapy and Ranibizumab in Macular Degeneration and Choroidal Neovascularization, sponsored by Novartis. Terminated at 12 sites in 12 countries. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2011-04-21.

Sponsored by Novartis · Phase 2/3, Interventional, and Treatment

Why this study was terminated
Study was terminated based on the results of analyses performed as planned at Month 12.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
255
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 18 studies testing verteporfin in Macular Degeneration — none open to participants now, none under way, none of them phase 3. Verteporfin · Macular Degeneration.

Enrollment
5th of 17
255 · median 60
Started
2007
with 4 others
Phase 2/3
Only one
of the 18
Registered
8th of 18
by date
Lead sponsor
4 of 18
Novartis

Among the 18 studies testing verteporfin in Macular Degeneration, this one is the 5th largest by enrollment of the 17 interventional ones that give a count, is one of 5 that started in 2007, is the only one in phase 2/3, and was the 8th registered.

Macular Degeneration

1,459 studies on the registry are indexed under Macular Degeneration; 236 are open to participants now.

Browse Macular Degeneration studies →

Open to participants now

None of the 18 studies testing verteporfin in Macular Degeneration is open now. The open studies under Macular Degeneration, anywhere →

About verteporfin

Verteporfin: first FDA approval 2000 (VISUDYNE), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 165 Macular Degeneration studies recruiting now, 116 (70%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 18 studies testing verteporfin in Macular Degeneration as a file.
02

Study summary

This study will evaluate the effect of combination therapy with verteporfin photodynamic therapy and ranibizumab on visual acuity compared to ranibizumab monotherapy and the durability of response observed in patients with choroidal neovascularization secondary to age-related macular degeneration

03

Conditions studied

  • Macular Degeneration
  • Choroidal Neovascularization

Keywords

  • Age-related macular degeneration
  • AMD
  • Choroidal neovascularization
  • Verteporfin
  • Ranibizumab
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects of either gender age 50 years or older
  • Subfoveal choriodal neovascularization (CNV) due to age-related macular degeneration (AMD)

Exclusion criteria

Exclusion Criteria:

  • Choriodal neovascularization due to causes other than AMD
  • Prior treatment for neovascular AMD in the study eye

Other protocol-defined inclusion/exclusion criteria may apply

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
255 participants (actual)

Study arms

  • Experimental
    Verteporfin + Ranibizumab

    Verteporfin (6 mg/m\^2) photodynamic therapy (PDT) and ranibizumab (0.5 mg). Patients received three consecutive monthly ranibizumab injections starting on Day 1, and then as needed at intervals of at least 30 days based on retreatment criteria. These patients also received verteporfin PDT on Day 1 and then as needed from Month 3 at intervals of at least 90 days based on the retreatment criteria. From month 3 onward, retreatments were determined based on study-specific retreatment criteria that included retinal thickness by Optical Coherence Tomography (OCT), sub-retinal hemorrhage evaluated by ophthalmoscopic examination, visual acuity assessed using Early treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart and CNV leakage assessed by fluorescein angiography (FA).

    Drug: Verteporfin Photodynamic Therapy · Drug: Ranibizumab

  • Active comparator
    Ranibizumab Monotherapy

    Patients received three consecutive monthly ranibizumab injections starting on Day 1 and then as needed from Month 3 based on the retreatment criteria. These patients were also administered verteporfin placebo infusion with sham PDT on Day 1 and then as needed from Month 3 at intervals of at least 90 days based on the retreatment criteria. From month 3 onward, retreatments were determined based on study-specific retreatment criteria that included retinal thickness by Optical Coherence Tomography (OCT), sub-retinal hemorrhage evaluated by ophthalmoscopic examination, visual acuity assessed using Early treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart and CNV leakage assessed by fluorescein angiography (FA).

    Drug: Ranibizumab · Drug: Placebo

Interventions

  • After a 10-minute intravenous infusion of verteporfin at a dose of 6 mg/m\^2 body surface area, verteporfin was activated by light application of 50 J/cm\^2 to the study eye, begun 15 minutes after the start of the infusion.

    Also known as: Visudyne

  • Ranibizumab 0.5 mg (0.05 mL of 10 mg/mL solution for injection) administered as an intravitreal injection

    Also known as: Lucentis

  • DrugPlacebo

    As a placebo for verteporfin photodynamic therapy (for masking purposes), patients were administered a 10-minute intravenous infusion of 5% dextrose solution, followed by light application of 50 J/cm\^2 to the study eye, begun 15 minutes after the start of infusion.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Best-corrected Visual Acuity (BCVA) at Month 12.

    BCVA score was based on the number of letters read correctly on the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart assessed at a starting distance of 4 meters. An ETDRS visual acuity score of 85 is approximately 20/20. An increase in the VA score indicates improvement in visual acuity.

    Time frame: Baseline and Month 12

  2. Percent of Participants With a Treatment-free Interval of at Least 3 Months Following the Month 2 Visit

    The number of patients with a ranibizumab treatment-free interval, ie, no active ranibizumab treatments for at least 3 months duration (at least 2 consecutive monthly visits), anytime following the Month 2 ranibizumab treatment. Only active ranibizumab treatments were considered.

    Time frame: Month 2 to Month 11

Secondary outcomes

  1. Percentage of Patients With Fluorescein Leakage in the Study Eye at Month 12

    The proportion of patients with leakage of the study eye was assessed at the Central Reading Center (CRC) using Fluorescein angiography (FA).

    Time frame: Month 12

  2. Mean Change in Total Area of Leakage (Observed) of the Study Eye at Month 12

    Fluorescein angiography (FA) was used to assess the mean change of leakage of the study eye at the Central Reading Center (CRC). A negative change from baseline indicates improvement, ie, less leakage.

    Time frame: Baseline and Month 12

  3. Mean Change in Central Retinal Thickness of the Study Eye at Month 12

    Optical coherence tomography (OCT) was used to assess the mean change in retinal thickness of the study eye at the Central Reading Center (CRC). A negative change from baseline indicates improvement, ie, less thickness.

    Time frame: Baseline and Month 12

07

Results

Posted Feb 4, 2011

Participant flow

Participant flow — Overall Study
MilestoneVerteporfin + RanibizumabRanibizumab
Started122133
Completed 12 month phase114126
Completed2632
Not completed96101
Withdrew: Adverse event53
Withdrew: Withdrawal by subject45
Withdrew: Lost to follow-up34
Withdrew: Administrative problems8086
Withdrew: Protocol violation10
Withdrew: Death22
Withdrew: Subject no longer requires study drug11

Outcome measures

PrimaryChange From Baseline in Best-corrected Visual Acuity (BCVA) at Month 12.

BCVA score was based on the number of letters read correctly on the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart assessed at a starting distance of 4 meters. An ETDRS visual acuity score of 85 is approximately 20/20. An increase in the VA score indicates improvement in visual acuity.

Time frame:
Baseline and Month 12
Reported as:
Mean · Letters
Change From Baseline in Best-corrected Visual Acuity (BCVA) at Month 12.
LettersVerteporfin + RanibizumabRanibizumab
Baseline54.6 ± 13.555.1 ± 12.3
Month 1257.1 ± 18.359.4 ± 18.8
Change from Baseline2.5 ± 14.824.4 ± 15.92
PrimaryPercent of Participants With a Treatment-free Interval of at Least 3 Months Following the Month 2 Visit

The number of patients with a ranibizumab treatment-free interval, ie, no active ranibizumab treatments for at least 3 months duration (at least 2 consecutive monthly visits), anytime following the Month 2 ranibizumab treatment. Only active ranibizumab treatments were considered.

Time frame:
Month 2 to Month 11
Reported as:
Number · Percentage of Participants
Percent of Participants With a Treatment-free Interval of at Least 3 Months Following the Month 2 Visit
Percentage of ParticipantsVerteporfin + RanibizumabRanibizumab
Percent of Participants With a Treatment-free Interval of at Least 3 Months Following the Month 2 Visit95.892.2
SecondaryPercentage of Patients With Fluorescein Leakage in the Study Eye at Month 12

The proportion of patients with leakage of the study eye was assessed at the Central Reading Center (CRC) using Fluorescein angiography (FA).

Time frame:
Month 12
Reported as:
Number · Percentage of participants
Percentage of Patients With Fluorescein Leakage in the Study Eye at Month 12
Percentage of participantsVerteporfin + RanibizumabRanibizumab
Percentage of Patients With Fluorescein Leakage in the Study Eye at Month 1228.925.2
SecondaryMean Change in Total Area of Leakage (Observed) of the Study Eye at Month 12

Fluorescein angiography (FA) was used to assess the mean change of leakage of the study eye at the Central Reading Center (CRC). A negative change from baseline indicates improvement, ie, less leakage.

Time frame:
Baseline and Month 12
Reported as:
Mean · mm^2
Mean Change in Total Area of Leakage (Observed) of the Study Eye at Month 12
mm^2Verteporfin + RanibizumabRanibizumab
Baseline7.4 ± 4.638.1 ± 5.82
Month 122.2 ± 4.882.0 ± 4.68
Change from Baseline-5.3 ± 5.32-6.1 ± 6.44
SecondaryMean Change in Central Retinal Thickness of the Study Eye at Month 12

Optical coherence tomography (OCT) was used to assess the mean change in retinal thickness of the study eye at the Central Reading Center (CRC). A negative change from baseline indicates improvement, ie, less thickness.

Time frame:
Baseline and Month 12
Reported as:
Mean · μm
Mean Change in Central Retinal Thickness of the Study Eye at Month 12
μmVerteporfin + RanibizumabRanibizumab
Baseline335.2 ± 94.7339.8 ± 125.6
Month 12219.9 ± 61.1232.0 ± 54.5
Change from Baseline-115.3 ± 98.7-107.7 ± 124.6

Adverse events

Collected over Includes cumulative data through 24 months.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Verteporfin + Ranibizumab—25/122 (20.5%)64/122 (52.5%)
Ranibizumab—28/133 (21.1%)63/133 (47.4%)
Most frequent serious events
Showing 10 of 80
Most frequent serious events
EventVerteporfin + RanibizumabRanibizumab
FALLInjury, poisoning and procedural complications4/1222/133
CEREBROVASCULAR ACCIDENTNervous system disorders1/1224/133
CARDIAC FAILURECardiac disorders2/1220/133
MYOCARDIAL INFARCTIONCardiac disorders2/1220/133
VISUAL ACUITY REDUCED (Study eye)Eye disorders2/1221/133
PERIPHERAL ARTERIAL OCCLUSIVE DISEASEVascular disorders2/1220/133
CATARACT (Study eye)Eye disorders0/1222/133
RENAL NEOPLASMNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1222/133
DIZZINESSNervous system disorders0/1222/133
ANGINA PECTORISCardiac disorders1/1221/133
Most frequent other events
Showing 10 of 11
Most frequent other events
EventVerteporfin + RanibizumabRanibizumab
HYPERTENSIONVascular disorders19/12213/133
NASOPHARYNGITISInfections and infestations18/12215/133
INTRAOCULAR PRESSURE INCREASED (Study eye)Investigations11/1228/133
EYE PAIN (Study eye)Eye disorders10/1228/133
CONJUNCTIVAL HAEMORRHAGE (Study eye)Eye disorders4/12210/133
OCULAR HYPERAEMIA (Study eye)Eye disorders7/12210/133
INFLUENZAInfections and infestations3/1229/133
ARTHRALGIAMusculoskeletal and connective tissue disorders8/1223/133
MACULAR DEGENERATION (Fellow eye)Eye disorders4/1228/133
RETINAL HAEMORRHAGE (Study eye)Eye disorders7/1225/133

Baseline characteristics

Age Continuous
Age Continuous(years)Verteporfin + RanibizumabRanibizumabTotal
Mean76.8 ± 7.6575.5 ± 7.4476.1 ± 7.55
Sex: Female, Male
Sex: Female, Male(Participants)Verteporfin + RanibizumabRanibizumabTotal
Female7874152
Male4459103
08

Study locations

12 sites
  • Novartis Investigative site
    Wien, Austria
  • Novartis Investigative site
    Antwerpen, Belgium
  • Novartis Investigative site
    Aalborg, Denmark
  • Novartis Investigative site
    Creteil, France
  • Novartis Investigative site
    Regensburg, Germany
  • Novartis Investigative site
    Budapest, Hungary
  • Novartis Investigative site
    Firenze, Italy
  • Novartis Investigative site
    Rotterdam, Netherlands
  • Novartis Investigative site
    Warszawa, Poland
  • Novartis Investigative site
    Madrid, Spain
  • Novartis Investigative site
    Geneve, Switzerland
  • Novartis Investigative site
    Manchester, United Kingdom
09

References and documents

Publications

  • Ritter M, Simader C, Bolz M, Deak GG, Mayr-Sponer U, Sayegh R, Kundi M, Schmidt-Erfurth UM. Intraretinal cysts are the most relevant prognostic biomarker in neovascular age-related macular degeneration independent of the therapeutic strategy. Br J Ophthalmol. 2014 Dec;98(12):1629-35. doi: 10.1136/bjophthalmol-2014-305186. Epub 2014 Jul 30. PubMed 25079064 ↗
  • Larsen M, Schmidt-Erfurth U, Lanzetta P, Wolf S, Simader C, Tokaji E, Pilz S, Weisberger A; MONT BLANC Study Group. Verteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration: twelve-month MONT BLANC study results. Ophthalmology. 2012 May;119(5):992-1000. doi: 10.1016/j.ophtha.2012.02.002. Epub 2012 Mar 17. PubMed 22424834 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2007, a primary completion of Jul 2009 and a completion of Jul 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2011, 1 year 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 8, 2007
First posted
Feb 9, 2007
Start
May 2007
Primary completionActual
Jul 2009
CompletionActual
Jul 2009
Results first posted
Feb 4, 2011
Last update
Apr 21, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 21, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00433017
Lead sponsor
Novartis
First posted
Feb 9, 2007
Start date
May 2007
Primary completion
Jul 2009
Completion
Jul 2009
Results posted
Feb 4, 2011
Last update
Apr 21, 2011

Study contacts

Novartis
study chair · Novartis
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Verteporfin

Start the discussion